Mazdutide: Trial Results, China Approval and US Status (2026)

Quick answers

What is it?: A weekly injection from Eli Lilly that Innovent Biologics develops in China under a 2019 license⁵⁶. This lab-made peptide acts like two hormones at once, GLP-1 and glucagon⁶. China approved it in 2025 as Xinermei, for weight management and type 2 diabetes⁶.
Does it work?: Yes, in large trials, mostly in China. Over 48 weeks, adults with obesity or overweight lost 11.0% to 14.0% of their weight, versus a 0.3% gain on placebo⁴. At a higher dose over 60 weeks, adults with obesity lost 16.65% versus 1.50% on placebo⁷.
Is it safe?: Not fully known. Gut side effects are common: in a 60-week trial, 53.1% vomited and 46.9% had nausea, versus 1.3% and 3.2% on placebo⁷. In a US trial, 20% stopped the highest dose tested (16 mg) because of side effects⁸.
Is it legal?: It is approved in China and Macau, but not in the US³⁵. By our reading, US pharmacies may not make it⁹¹⁰. FDA has warned companies that sold it falsely labeled “for research purposes”¹¹. In sport, it is likely allowed, by our reading¹²¹³.
What is in the vials?: More than a third of tested samples failed. Of 29 tests that Finnrick, an independent testing service, listed from April to November 2025, 11 failed¹⁴. A pass needs at least 99.5% purity and a dose within 35% of the label¹⁴.

What it is

Mazdutide (development codes LY3305677 and IBI362) is a lab-made peptide of 34 amino acids that activates two hormone receptors: the receptor for GLP-1 (glucagon-like peptide-1) and the glucagon receptor⁶¹⁵. It is a long-acting synthetic version of oxyntomodulin, a natural gut hormone whose appetite-reducing effect comes through the GLP-1 receptor and whose rise in energy expenditure comes through the glucagon receptor¹⁶. Innovent says the glucagon receptor activity may also raise energy expenditure and improve how the liver handles fat¹. A fatty-acid chain extends its half-life, so it is injected under the skin once a week¹⁶.

Mazdutide is an Eli Lilly molecule (LY3305677). In 2019 Innovent Biologics took an exclusive license from Lilly to develop and sell it in China, and Innovent lists its rights as covering mainland China, Hong Kong, Macau and Taiwan⁵. China’s National Medical Products Administration (NMPA) approved it in June 2025 for chronic weight management and in September 2025 for blood sugar control in type 2 diabetes¹²⁶. Macau followed in October 2025 and January 2026⁵. Lilly has run its own Phase 1 and 2 trials in the US, the UK, Germany and Argentina⁸¹⁷.

Benefits: what the research shows

Mazdutide has been tested in large controlled trials, nearly all in China. In GLORY-1, 610 Chinese adults with obesity or overweight (BMI 28 or more, or 24 to under 28 with a weight-related condition) received 4 mg or 6 mg weekly or placebo for 48 weeks; weight changed by -11.0% and -14.0% versus +0.3% on placebo, counting people who stopped treatment or started other weight-loss therapy⁴. By the efficacy estimand, which assumes everyone stayed on treatment, Innovent reported weight changes at week 48 of -12.0%, -14.8% and -0.5%; in people whose liver fat was at least 10% at the start, liver fat fell by 65.9% and 80.2% versus 5.3%¹. GLORY-2 tested 9 mg against placebo in 461 Chinese adults with obesity for 60 weeks: weight fell 16.65% versus 1.50%, and 84.3% versus 33.1% lost at least 5%⁷. In type 2 diabetes, DREAMS-1 (320 adults) lowered HbA1c (average blood sugar) by 1.57 and 2.15 points on 4 and 6 mg versus 0.14 on placebo at 24 weeks¹⁹, and DREAMS-2 (731 adults) lowered HbA1c by 0.24 and 0.30 points more than dulaglutide 1.5 mg, and weight by 3.78 and 5.76 percentage points more, at 28 weeks²⁰. Innovent reported that in DREAMS-3, an open-label trial in 349 adults with type 2 diabetes and obesity, 6 mg lowered weight by 10.29% versus 6.00% on semaglutide 1 mg over 32 weeks²¹. There are important limits. All 11 Phase 3 trials that list mazdutide on ClinicalTrials.gov are in China, and 9 are sponsored by Innovent¹⁷; Innovent funded GLORY-1⁴. Outside China the evidence is smaller. In a Lilly-funded US Phase 2 trial of 179 adults, weight fell 7.3% (3 mg, later 6 mg), 15.6% (10 mg) and 18.1% (16 mg) versus 0.9% on placebo at 32 weeks by the efficacy estimand, with further losses by 48 weeks⁸. In a Lilly-funded US Phase 1 trial of 32 adults, weight fell 20.0% and 21.0% over 20 weeks at a 16 mg target dose, versus 0.1% on placebo²². DREAMS-3 has been reported only in a company press release²¹. The longest published trial ran 60 weeks⁷, so long-term effects and effects on heart attacks and strokes are unknown. Lilly’s public pipeline (data as of 5 August 2026) does not list mazdutide, though Lilly says some molecules are not identified for competitive reasons²³.

Key human studies

Study	Design	People	Dose and route	Result
Ji et al., N Engl J Med 2025 (GLORY-1)⁴PubMed · DOI · NCT05607680	Phase 3 randomized, double-blind, placebo-controlled trial in China (1:1:1), 48 weeks; adults with BMI 28 or more, or 24 to under 28 with a weight-related condition	610	4 mg or 6 mg subcutaneous once weekly, or placebo	Body weight -11.00% (4 mg) and -14.01% (6 mg) vs +0.30% with placebo at week 48 (treatment-policy estimand). Adverse events led 1.5%, 0.5% and 1.0% to stop; gastrointestinal events were the most common, mostly mild to moderate⁴.
Gao et al., JAMA 2026 (GLORY-2)⁷PubMed · DOI · NCT06164873	Phase 3 randomized, double-blind, placebo-controlled trial (2:1), 60 weeks, at 27 hospitals in China; adults with BMI 30 or more, 16.1% with type 2 diabetes	461	9 mg subcutaneous once weekly, or placebo, with diet and activity advice	Body weight -16.65% vs -1.50% with placebo; 84.3% vs 33.1% lost 5% or more. Vomiting 53.1% vs 1.3%, nausea 46.9% vs 3.2%, diarrhea 39.4% vs 6.5%; adverse events led 2.9% vs 0% to stop⁷.
Guo et al., Nature 2026 (DREAMS-2)²⁰PubMed · DOI · NCT05606913	Phase 3 randomized trial against an active comparator (1:1:1), 28 weeks; Chinese adults with type 2 diabetes on oral diabetes drugs	731	4 mg or 6 mg subcutaneous once weekly, or dulaglutide 1.5 mg once weekly	HbA1c down 0.24 and 0.30 points more than with dulaglutide; body weight down 3.78 and 5.76 percentage points more. Gastrointestinal adverse events were more common than with dulaglutide²⁰.
Zhu et al., Nature 2026 (DREAMS-1)¹⁹PubMed · DOI · NCT05628311	Phase 3 randomized, placebo-controlled trial (1:1:1), 24 weeks, then 24 weeks of extended mazdutide treatment; Chinese adults with type 2 diabetes not controlled by diet and exercise (mean HbA1c 8.24%)	320	4 mg or 6 mg subcutaneous once weekly, or placebo	HbA1c -1.57 and -2.15 points vs -0.14 with placebo at week 24; body weight -5.61% and -7.81% vs -1.26%¹⁹.
Hsia et al., Lancet Diabetes Endocrinol 2026⁸PubMed · DOI · NCT06124807	Phase 2 randomized, double-blind, placebo-controlled trial, 48 weeks, at 24 US centers; adults with obesity or overweight, without type 2 diabetes	179	3 mg then 6 mg (from week 32), 10 mg or 16 mg subcutaneous once weekly, or placebo	Body weight -7.3%, -15.6% and -18.1% vs -0.9% with placebo at 32 weeks (efficacy estimand), with further losses by 48 weeks. Adverse events led 20% on 16 mg to stop, mainly gastrointestinal⁸.
Bhattachar et al., Diabetes Obes Metab 2025²²PubMed · DOI · NCT05623839	Phase 1 randomized, double-blind, placebo-controlled trial, 20 weeks, in the US; adults with overweight or obesity, without diabetes	32	Two dose-escalation schemes to a 16 mg target dose, subcutaneous once weekly, or placebo	Body weight -20.0% and -21.0% in the two mazdutide groups vs -0.1% with placebo; no serious adverse events. Pulse rose by 10 beats per minute or more at two consecutive visits in 91.7% vs 37.5% on placebo²².

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

No dose is approved in the US. In China, the approved doses are 4 mg and 6 mg once weekly⁵, and a 9 mg dose was under review as of 25 August 2026³². Trials used 4 mg or 6 mg weekly for 48 weeks in obesity⁴ and for 24 or 28 weeks in type 2 diabetes¹⁹²⁰, and 9 mg weekly for 60 weeks in obesity⁷, all injected under the skin. Lilly’s US trials tested weekly doses of up to 16 mg⁸²².

In animal studies

Not summarized. Mazdutide has been tested directly in large human trials, so this entry does not rely on animal doses.

What users report

No community dosing page was cited for this compound.

Half-life: About 6 to 17 days¹⁶Range in a 12-week study in 36 Chinese adults with overweight or obesity, at doses up to 6 mg weekly (150.9 to 403.5 hours). A 12-week study in type 2 diabetes reported 6.1 to 28.1 days³⁸.
Routes: Subcutaneous injection once weekly (approved in China; the only route in the human studies we found)
No human data found for any other route

Every dose studied for Mazdutide, with sources →

Legal status

United States: Not approved by FDA for any use; Drugs@FDA lists no product containing mazdutide (data updated 6 October 2026)³. Eli Lilly’s public pipeline (data as of 5 August 2026) does not list mazdutide, though Lilly says some molecules are not identified for competitive reasons²³. Lilly has tested it in US trials: a Phase 2 obesity trial in 179 adults at 24 US centers⁸; a Phase 2 trial in alcohol use disorder with 308 US participants, completed on 19 May 2026, with no results posted as of 7 October 2026²⁴; and a master-protocol obesity study recruiting in the US and Argentina, with primary completion estimated for September 2027²⁵. All 7 Lilly-sponsored mazdutide records on ClinicalTrials.gov are Phase 1 or 2 trials, in the US, the UK, Germany and Argentina¹⁷. FDA says it has warned companies that illegally sold unapproved drugs containing mazdutide and other GLP-1 drugs, falsely labeled “for research purposes” or “not for human consumption” (page current 1 October 2026)¹¹. As of 7 October 2026, its warning-letter database listed four letters naming mazdutide, dated 10 December 2024 to 24 August 2026^2627282930.
US pharmacies: Not allowed, by our reading. Under section 503A, a pharmacy may compound from a bulk ingredient only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list⁹. No FDA-approved drug contains mazdutide³; approval in China does not make it a component of an FDA-approved drug. The bulks list in federal regulations names six substances, and mazdutide is not one of them³¹. It is in none of the three categories of FDA’s list of nominated substances (updated 14 May 2026)¹⁰, and FDA says it does not intend to place substances nominated on or after 7 January 2025 into those categories⁹. That is our reading of FDA’s general rules; we found no FDA statement on compounding mazdutide specifically.
Other countries: China: the NMPA approved mazdutide, sold as Xinermei, in June 2025 for long-term weight management, with diet and physical activity, in adults with a BMI of 28 or more, or 24 or more with at least one weight-related condition¹⁶. In September 2025 it approved mazdutide for blood sugar control in adults with type 2 diabetes, based on DREAMS-1 and DREAMS-2²⁶. The approved doses are 4 mg and 6 mg⁵, and a prefilled multi-dose pen (2 ml; 24 mg) was approved in May 2026³². Innovent announced on 25 November 2025 that China’s drug regulator had accepted for review an application for a 9 mg dose for adults with moderate to severe obesity, based on GLORY-2³³; it was still under review on 25 August 2026³². Macau approved mazdutide for weight management in October 2025 and for type 2 diabetes in January 2026⁵. Australia: mazdutide is not named in the Poisons Standard in force from 1 October 2026³⁴; how Australian law otherwise treats it was not verified. EU, UK and Canada: not verified.
Sport: Not prohibited, by our reading. Mazdutide is not named on WADA’s (World Anti-Doping Agency) 2026 Prohibited List or on the 2027 List published 21 September 2026, and neither List mentions GLP-1 or glucagon¹²¹³. On 21 September 2026 WADA said the status of GLP-1 receptor agonists such as semaglutide and tirzepatide will remain unchanged for 2027³⁵. WADA’s 2027 Monitoring Program, which tracks substances that are not banned, names only semaglutide and tirzepatide under GLP-1 agonists³⁶. Class S0 bans substances not covered elsewhere “with no current approval by any governmental regulatory health authority for human therapeutic use”¹². China approved mazdutide in 2025¹, so by our reading it falls outside S0 and is likely allowed. This is not a WADA ruling, and it rests on approvals in China and Macau, so athletes should not rely on it. WADA’s note on the 2027 List says that even if a peptide is not named, “utmost caution should be taken as it may still be prohibited”³⁷.

Mazdutide in the legal tracker →

Quality and the gray market

What testing finds

Finnrick, an independent testing service, listed 29 mazdutide tests dated 25 April 2025 to 25 November 2025: 18 passed and 11 failed (as displayed on 7 October 2026)¹⁴. Its default “Purity focus” standard requires purity of at least 99.5% and a measured dose within 35% of the label¹⁴. A Finnrick correction dated 1 August 2025 says one vendor’s mazdutide results were under review¹⁴. Finnrick also offers free mail-in testing to US users, so by our reading its results may not represent the whole market¹⁴.

How it is sold

Outside China, mazdutide is sold online as vials labeled for research use. FDA says companies have illegally sold unapproved drugs containing mazdutide and other GLP-1 drugs, falsely labeled “for research purposes” or “not for human consumption”, directly to consumers for human use with dosing instructions (page current 1 October 2026)¹¹. As of 7 October 2026, FDA’s warning-letter database listed four letters naming mazdutide²⁶. On 10 December 2024 FDA wrote to Summit Research Peptides, whose website, reviewed in October 2024, offered “Mazdutide” alongside semaglutide, tirzepatide, retatrutide and cagrilintide under “RESEARCH USE ONLY” labels²⁷, and to Xcel Research LLC, which offered “MAZDUTIDE” and “SURVODUTIDE”²⁸. In a letter of 31 March 2026, FDA quoted a Prime Sciences product page: “In a phase 3 trial (GLORY-1), once-weekly mazdutide led to an average body weight reduction of up to 14.8%”, on products labeled for “laboratory research purposes only”²⁹. That figure matches Innovent’s 48-week efficacy-estimand result for 6 mg¹. On 24 August 2026 FDA told NuScience Peptides LLC that its “Mazdutide” product was an unapproved new drug³⁰. We found no verified price or demand data.

Side effects and risks

Gut side effects are very common: in GLORY-2, 53.1% vomited, 46.9% had nausea and 39.4% had diarrhea on 9 mg, versus 1.3%, 3.2% and 6.5% on placebo⁷. In a US trial, 20% stopped the 16 mg dose because of adverse events, mainly gastrointestinal⁸.
Pulse rises: in a small US trial, pulse rose by 10 beats per minute or more at two consecutive visits in 91.7% of people on mazdutide versus 37.5% on placebo²². An early study found mild, symptomless heart findings on ECG in three people on mazdutide¹⁶.
Some people make antibodies against the drug: 2 of 24 on mazdutide in one early study¹⁶, and 4 of 24 versus 1 of 12 on placebo in another, none of them neutralizing³⁸.
Long-term effects, and effects on heart attacks, strokes and deaths, are unknown; the longest published trial ran 60 weeks⁷.
Gray-market products are of unknown quality: 11 of 29 Finnrick tests of mazdutide failed¹⁴.
Legal risk: in the US, mazdutide sold for human use is an unapproved new drug, and FDA has warned sellers¹¹³⁰.

Questions people ask

Is mazdutide FDA approved?

No. Drugs@FDA lists no product containing it (data updated 6 October 2026)³. It is approved in China, as Xinermei, and in Macau⁵⁶.

What is Xinermei?

Xinermei is the brand name of mazdutide in China, where Innovent Biologics holds the rights to sell it⁵⁶. China approved it in June 2025 for long-term weight management in adults with a BMI of 28 or more, or 24 or more with a weight-related condition, and in September 2025 for type 2 diabetes⁶.

How much weight do people lose on mazdutide?

In GLORY-1, Chinese adults with obesity or overweight lost 11.0% (4 mg) and 14.0% (6 mg) of their weight over 48 weeks, versus a 0.3% gain on placebo⁴. In GLORY-2, adults with obesity on 9 mg lost 16.65% over 60 weeks, versus 1.50% on placebo⁷. A US trial found 18.1% loss at 32 weeks on 16 mg, versus 0.9% on placebo, by the efficacy estimand⁸.

Mazdutide vs semaglutide: which works better?

In DREAMS-3, an open-label trial in 349 Chinese adults with type 2 diabetes and obesity, Innovent reported that 6 mg mazdutide lowered weight by 10.29% versus 6.00% on semaglutide 1 mg over 32 weeks, and HbA1c by 2.03 versus 1.84 points²¹. These results come from a company press release. A second head-to-head trial, in fatty liver disease, was still running when we checked⁵¹⁷.

Is Lilly developing mazdutide in the US?

Lilly has tested it in US trials, including a Phase 2 obesity trial in 179 adults and a Phase 2 trial in alcohol use disorder that finished in May 2026⁸²⁴. We found no Lilly announcement of plans to seek FDA approval, and its public pipeline (data as of 5 August 2026) does not list mazdutide²³.

What are the side effects of mazdutide?

Mostly gut effects: in GLORY-2, 53.1% vomited, 46.9% had nausea and 39.4% had diarrhea on 9 mg, versus 1.3%, 3.2% and 6.5% on placebo, and most cases were mild to moderate⁷. Pulse also rose in most people in a small US trial²².

Is mazdutide banned in sport?

It is not named on WADA’s 2026 or 2027 Prohibited List¹²¹³. Because it is approved in China, by our reading it falls outside S0, WADA’s ban on non-approved substances, so it is likely allowed¹¹². This is not a WADA ruling.

What is still unknown

Whether and when Lilly will seek approval in the US or Europe.
Peer-reviewed results of DREAMS-3 (company press release only, as of 7 October 2026).
Why Innovent’s GLORY-2 press release of 19 November 2025 gave larger weight losses than the JAMA paper; the release did not name its estimand. This entry uses the paper.
Effects beyond 60 weeks, and on heart attacks, strokes and deaths.
Results of Lilly’s alcohol use disorder trial (completed 19 May 2026; no results posted as of 7 October 2026).
China’s decision on the 9 mg dose (under review as of 25 August 2026).
The Chinese characters of the brand name Xinermei (not verified).
Whether mazdutide has a USP or NF monograph (not checked).
UK, EU, Canadian and wider Australian rules (not verified).
WADA has not ruled on mazdutide by name; the likely-allowed status is our reading of the List.

Sources

1Voluntary Announcement: First Dual GCG/GLP-1 Receptor Agonist Mazdutide Received Approval by the National Medical Products Administration for Chronic Weight Management Innovent Biologics, Inc. (HKEXnews), 27 Jun 2025. www1.hkexnews.hk
2Voluntary Announcement: Mazdutide Received Approval from China’s National Medical Products Administration for Glycemic Control in Adults with Type 2 Diabetes Innovent Biologics, Inc. (HKEXnews), 19 Sep 2025. www1.hkexnews.hk
3Drugs@FDA via openFDA: search for active ingredient mazdutide (no matches) U.S. Food and Drug Administration (openFDA), 6 Oct 2026. api.fda.gov · data query
4Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight New England Journal of Medicine, 12 Jun 2025. pubmed.ncbi.nlm.nih.gov
5Annual Report 2025 Innovent Biologics, Inc. (HKEXnews), 28 Apr 2026. www1.hkexnews.hk
6Mazdutide: First Approval Drugs, Dec 2025. pubmed.ncbi.nlm.nih.gov
7Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA, 4 Aug 2026. pubmed.ncbi.nlm.nih.gov
8Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial The Lancet Diabetes & Endocrinology, 21 Aug 2026. pubmed.ncbi.nlm.nih.gov
9Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
10Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
11FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration, 1 Oct 2026. fda.gov
12World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
13World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
14Mazdutide Safety Testing Results & Vendor Ratings Finnrick, accessed 7 Oct 2026. finnrick.com
15KEGG DRUG: Mazdutide (D12225) KEGG, Kanehisa Laboratories, accessed 7 Oct 2026. kegg.jp
16IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study EClinicalMedicine, Sep 2021. pubmed.ncbi.nlm.nih.gov
17ClinicalTrials.gov search: studies with the intervention mazdutide, LY3305677 or IBI362 (45 records) ClinicalTrials.gov, accessed 7 Oct 2026. clinicaltrials.gov
18Proposed International Nonproprietary Names: List 126 (WHO Drug Information, Vol. 35, No. 4) World Health Organization, 2021. cdn.who.int
19Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature, Apr 2026. pubmed.ncbi.nlm.nih.gov
20Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature, Apr 2026. pubmed.ncbi.nlm.nih.gov
21Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 Innovent Biologics (PR Newswire), 26 Oct 2025. prnewswire.com
22Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial Diabetes, Obesity and Metabolism, Nov 2025. pubmed.ncbi.nlm.nih.gov
23Clinical Development Pipeline Eli Lilly and Company, 5 Aug 2026. lilly.com
24A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder (NCT06817356) ClinicalTrials.gov, 16 Jul 2026. clinicaltrials.gov
25A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (NCT06143956) ClinicalTrials.gov, 8 Sep 2026. clinicaltrials.gov
26Warning Letters (database search for mazdutide) U.S. Food and Drug Administration, accessed 7 Oct 2026. fda.gov
27Warning letter to Summit Research Peptides (MARCS-CMS 695607) U.S. Food and Drug Administration, 10 Dec 2024. fda.gov
28Warning letter to Xcel Research LLC (MARCS-CMS 694608) U.S. Food and Drug Administration, 10 Dec 2024. fda.gov
29Warning letter to Prime Sciences (MARCS-CMS 721805) U.S. Food and Drug Administration, 31 Mar 2026. fda.gov
30Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
3121 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, as of 25 September 2026) Electronic Code of Federal Regulations (eCFR), 25 Sep 2026. ecfr.gov
32Interim Results Announcement for the Six Months Ended 30 June 2026 Innovent Biologics, Inc. (HKEXnews), 25 Aug 2026. www1.hkexnews.hk
33Mazdutide 9mg Supplementary Application Accepted for Review by China’s NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population Innovent Biologics (PR Newswire), 25 Nov 2025. prnewswire.com
34Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
35WADA publishes 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
36The 2027 Monitoring Program World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
37Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
38A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes Nature Communications, 24 Jun 2022. pubmed.ncbi.nlm.nih.gov

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.